CN1070176C - 2,4-二磺酰苯基丁基硝酮,它的盐类及它们作为药物的应用 - Google Patents

2,4-二磺酰苯基丁基硝酮,它的盐类及它们作为药物的应用 Download PDF

Info

Publication number
CN1070176C
CN1070176C CN94194993A CN94194993A CN1070176C CN 1070176 C CN1070176 C CN 1070176C CN 94194993 A CN94194993 A CN 94194993A CN 94194993 A CN94194993 A CN 94194993A CN 1070176 C CN1070176 C CN 1070176C
Authority
CN
China
Prior art keywords
medicine
purposes
pharmaceutically useful
compound
pbn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94194993A
Other languages
English (en)
Chinese (zh)
Other versions
CN1156447A (zh
Inventor
J·M·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of CN1156447A publication Critical patent/CN1156447A/zh
Application granted granted Critical
Publication of CN1070176C publication Critical patent/CN1070176C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN94194993A 1993-12-23 1994-12-22 2,4-二磺酰苯基丁基硝酮,它的盐类及它们作为药物的应用 Expired - Fee Related CN1070176C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US08/173,579 1993-12-23

Publications (2)

Publication Number Publication Date
CN1156447A CN1156447A (zh) 1997-08-06
CN1070176C true CN1070176C (zh) 2001-08-29

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194993A Expired - Fee Related CN1070176C (zh) 1993-12-23 1994-12-22 2,4-二磺酰苯基丁基硝酮,它的盐类及它们作为药物的应用

Country Status (29)

Country Link
US (4) US5488145A (de)
EP (1) EP0736004B1 (de)
JP (3) JP3412821B2 (de)
KR (1) KR100370522B1 (de)
CN (1) CN1070176C (de)
AT (1) ATE192736T1 (de)
AU (1) AU679835B2 (de)
BR (2) BR9408378A (de)
CA (1) CA2179521C (de)
CZ (1) CZ289629B6 (de)
DE (1) DE69424441T2 (de)
DK (1) DK0736004T3 (de)
ES (1) ES2145264T3 (de)
FI (1) FI111718B (de)
GR (1) GR3034134T3 (de)
HK (2) HK1001768A1 (de)
HR (1) HRP950358B1 (de)
HU (1) HU221167B1 (de)
MY (1) MY114178A (de)
NO (1) NO306457B1 (de)
NZ (1) NZ279025A (de)
PL (1) PL185189B1 (de)
PT (1) PT736004E (de)
RU (1) RU2159231C2 (de)
SG (1) SG64903A1 (de)
SK (1) SK282403B6 (de)
TW (1) TW299315B (de)
UA (1) UA45964C2 (de)
WO (1) WO1995017876A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
ES2239194T3 (es) * 1995-09-11 2005-09-16 Aventis Pharmaceuticals Inc. Nitronas ciclicas y composiciones farmaceuticas que las contienen.
CA2235765C (en) 1995-11-17 2006-04-04 David A. Becker Azulenyl nitrone spin trapping agents, methods of making and using same
EP0949915A4 (de) * 1996-04-17 2001-07-04 Oklahoma Med Res Found Behandlung von mit aids-virus (hiv-1) infektion verbundenen demenz mit nitrone enthaltendem freien radikalen falle
JP2000514822A (ja) * 1996-07-19 2000-11-07 センター ファーマシューティカルズ，インコーポレイテッド フランニトロン化合物
TW429241B (en) 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
EP1047683A1 (de) * 1998-01-16 2000-11-02 Centaur Pharmaceuticals, Inc. Thioetherfuranyl-nitronderivate
CN1136212C (zh) * 1998-01-16 2004-01-28 桑道药品有限公司 噻吩硝酮化合物
WO1999045909A2 (en) * 1998-03-13 1999-09-16 Centaur Pharmaceuticals Use of nitrone compounds for the inhibition of angiogenesis
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
DE60024588T2 (de) 1999-01-25 2006-08-17 National Jewish Medical And Research Center, Denver Substituierte porphyrine und deren therapeutische verwendungen
BR0010099A (pt) * 1999-04-28 2002-06-04 Univ Kingston Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
WO2001028578A2 (en) * 1999-10-22 2001-04-26 Wrair A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
WO2001051459A1 (en) * 2000-01-10 2001-07-19 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
SE0000056D0 (sv) 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US6835754B2 (en) 2001-01-08 2004-12-28 Renovis, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
EP1817305A2 (de) * 2004-11-16 2007-08-15 Neurochem (International) Limited Verbindungen zur behandlung von cns- und amyloidassoziierten krankheiten
US8044100B2 (en) * 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
ES2352801T3 (es) * 2005-12-22 2011-02-23 Kiacta Sàrl Tratamiento de nefropatía diabética.
EP2054047B1 (de) * 2006-07-25 2014-12-17 Hough Ear Institute Verfahren zur behandlung von akutem akustischem trauma
ES2891278T3 (es) 2006-10-12 2022-01-26 Bhi Lp Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
CA2673022A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
WO2009042196A2 (en) 2007-09-26 2009-04-02 St. Jude Medical, Inc. Collapsible prosthetic heart valves
JP5611056B2 (ja) 2008-02-12 2014-10-22 トスク インコーポレーティッド 毒性を低減するためのドキソルビシンアジュバントおよびその使用法
MX2010012593A (es) 2008-05-23 2011-03-04 Nat Jewish Health Metodos para el tratamiento de lesion asociada con exposicion a especie alcalina.
AU2009288057B2 (en) * 2008-09-02 2014-07-03 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
EP2670403B1 (de) * 2011-02-04 2021-08-18 Hough Ear Institute Verfahren zur behandlung von gehirnverletzungen
CN110248650A (zh) 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
EP3570826A4 (de) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. Formulierungen von n-acetylcystein und deren verwendungen
CN111132672A (zh) 2017-09-20 2020-05-08 俄克拉荷马医学研究基金会 抗药性胶质瘤的治疗
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
US20210137861A1 (en) 2018-05-03 2021-05-13 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
JP2022500407A (ja) 2018-09-12 2022-01-04 ハフ イアー インスティテュート 人工内耳手術に伴う難聴の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
SG64903A1 (en) 1999-05-25
JPH09507232A (ja) 1997-07-22
ES2145264T3 (es) 2000-07-01
US5508305A (en) 1996-04-16
DK0736004T3 (da) 2000-10-09
PL185189B1 (pl) 2003-03-31
PL315154A1 (en) 1996-10-14
DE69424441T2 (de) 2000-10-12
NO962637L (no) 1996-08-13
SK78896A3 (en) 1997-09-10
US5488145A (en) 1996-01-30
HU221167B1 (en) 2002-08-28
WO1995017876A3 (en) 1995-08-10
CZ177596A3 (en) 1996-12-11
FI962589A (fi) 1996-08-20
US5780510A (en) 1998-07-14
MY114178A (en) 2002-08-30
GR3034134T3 (en) 2000-11-30
CA2179521C (en) 2002-03-19
NO306457B1 (no) 1999-11-08
HU9601739D0 (en) 1996-08-28
US5475032A (en) 1995-12-12
HRP950358B1 (en) 2001-04-30
ATE192736T1 (de) 2000-05-15
JP3412821B2 (ja) 2003-06-03
CN1156447A (zh) 1997-08-06
AU679835B2 (en) 1997-07-10
BR1100626A (pt) 1999-11-23
EP0736004A1 (de) 1996-10-09
CA2179521A1 (en) 1995-07-06
UA45964C2 (uk) 2002-05-15
PT736004E (pt) 2000-09-29
KR100370522B1 (ko) 2003-05-16
NZ279025A (en) 1998-02-26
EP0736004B1 (de) 2000-05-10
NO962637D0 (no) 1996-06-20
WO1995017876A2 (en) 1995-07-06
HK1001768A1 (en) 1998-07-10
FI962589A0 (fi) 1996-06-20
JP2004075696A (ja) 2004-03-11
RU2159231C2 (ru) 2000-11-20
AU1552795A (en) 1995-07-17
HRP950358A2 (en) 1997-08-31
HUT76788A (en) 1997-11-28
CZ289629B6 (cs) 2002-03-13
BR9408378A (pt) 1997-08-19
TW299315B (de) 1997-03-01
HK1008294A1 (en) 1999-05-07
SK282403B6 (sk) 2002-01-07
DE69424441D1 (de) 2000-06-15
FI111718B (fi) 2003-09-15
JP2001010953A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
CN1070176C (zh) 2,4-二磺酰苯基丁基硝酮,它的盐类及它们作为药物的应用
JP5795714B2 (ja) アレナウイルス感染症の治療のための抗ウイルス薬
US10646460B2 (en) Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound
JP5393679B2 (ja) アレナウイルス感染症を治療するための抗ウイルス薬
US20200383930A1 (en) Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
EP3122360B1 (de) Prophylaktischer wirkstoff und/oder therapeutischer wirkstoff für diffuses grosszelliges b-zell-lymphom
BR112021005903A2 (pt) inibidores de vap-1
CN1230178A (zh) 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US10265317B2 (en) Combination of creatine, an omega-3 fatty acid, and citicoline
CN1126548C (zh) 透明质酸锌抗消化性溃疡的应用
JP7381500B2 (ja) 外傷性脳損傷を検出するための組成物および方法
AU2018309372A1 (en) Methods of treating behavior alterations
CN1329597A (zh) 治疗糖尿病及衰老相关性血管性并发症的吡啶鎓衍生物
CN1968686A (zh) 脒腙盐、组合物、制备方法和使用方法
JP2017039727A (ja) プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用
JP7535797B2 (ja) 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
CN1291720C (zh) 非镇静性巴比土酸衍生物
US11524000B2 (en) Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
CN1093906A (zh) 抗病毒剂
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
WO2006087935A1 (ja) フェノキサジニウム化合物を活性成分として含有する医薬組成物
CN1059901A (zh) 钙摄入抑制剂
CN1099285C (zh) 新的镇痉剂和消炎药的组合物及其制造方法
CN1844106A (zh) 羟苯磺酸烷基吡嗪药物及其制备方法和应用
JP4227121B2 (ja) 神経因性疼痛治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee